Top

Published in:

Open Access 01-07-2013 | Review

Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?

Authors: S. J. Cleland, B. M. Fisher, H. M. Colhoun, N. Sattar, J. R. Petrie

Published in: Diabetologia | Issue 7/2013

Abstract

In this review, we explore the concept of ‘double diabetes’, a combination of type 1 diabetes with features of insulin resistance and type 2 diabetes. After considering whether double diabetes is a useful concept, we discuss potential mechanisms of increased insulin resistance in type 1 diabetes before examining the extent to which double diabetes might increase the risk of cardiovascular disease (CVD). We then go on to consider the proposal that weight gain from intensive insulin regimens may be associated with increased CV risk factors in some patients with type 1 diabetes, and explore the complex relationships between weight gain, insulin resistance, glycaemic control and CV outcome. Important comparisons and contrasts between type 1 diabetes and type 2 diabetes are highlighted in terms of hepatic fat, fat partitioning and lipid profile, and how these may differ between type 1 diabetic patients with and without double diabetes. In so doing, we hope this work will stimulate much-needed research in this area and an improvement in clinical practice.

Teupe B, Bergis K (1991) Epidemiological evidence for “double diabetes”. Lancet 337:361–362PubMedCrossRef

Wilkin TJ (2009) The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type 1 as well as type II diabetes. Int J Obes 33:716–726CrossRef

Roglic G, Colhoun HM, Stevens LK, Lemkes HH, Manes C, Fuller JH (1998) Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med 15:418–426PubMedCrossRef

Erbey JR, Kuller LH, Becker DJ, Orchard TJ (1998) The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care 21:610–614PubMedCrossRef

Petrie JR, Pearson ER, Sutherland C (2011) Implications of genome wide association studies for the understanding of type 2 diabetes pathophysiology. Biochem Pharmacol 81:471–477PubMedCrossRef

Williams D, Erbey J, Becker D, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626–632PubMedCrossRef

Heptulla RA, Stewart A, Enocksson S et al (2003) In situ evidence that peripheral insulin resistance in adolescents with poorly controlled type 1 diabetes is associated with impaired suppression of lipolysis: a microdialysis study. Pediatr Res 53:830–835PubMedCrossRef

Perseghin G, Lattuada G, Danna M et al (2003) Insulin resistance, intramyocellular lipid content and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 285:E1174–E1181PubMed

Perseghin G, Lattuanda G, De Cobelli F et al (2005) Reduced intrahepatic fat content is associated with increased whole-body lipid oxidation in patients with type 1 diabetes. Diabetologia 48:2615–2621PubMedCrossRef

10.

Makimattila S, Virkamaki A, Malmstrom R, Urtiainen T, Yki-Jarvinen H (1996) Insulin resistance in type 1 diabetes mellitus: a major role for reduced glucose extraction. J Clin Endocrinol Metab 81:707–712PubMedCrossRef

11.

Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G (1993) Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342:883–887PubMedCrossRef

12.

Kacerovsky M, Brehm A, Chmelik M et al (2011) Impaired insulin stimulation of muscular ATP production in patients with type 1 diabetes. J Intern Med 269:189–199PubMedCrossRef

13.

Nadeau KJ, Regensteiner JG, Bauer TA et al (2010) Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab 95:513–521PubMedCrossRef

14.

Maahs DM, Hokanson JE, Wang H et al (2010) Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance. Diabetes 59:1771–1779PubMedCrossRef

15.

Maahs DM, Nadeau K, Snell-Bergeon JK et al (2011) Association of insulin sensitivity to lipids across the lifespan in people with type 1 diabetes. Diabet Med 28:148–155PubMedCrossRef

16.

Schauer IE, Snell-Bergeon JK, Bergman BC et al (2011) Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study. Diabetes 60:306–314PubMedCrossRef

17.

Orchard TJ, Olson JC, Erbey JR et al (2003) Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes. Diabetes Care 26:1374–1379PubMedCrossRef

18.

Zgibor JC, Ruppert K, Orchard TJ et al (2010) Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in type 1 diabetes risk model. Diabetes Res Clin Pract 88:314–321PubMedCrossRef

19.

Kilpatrick ES, Rigby AS, Atkin SL (2007) Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care 30:707–712PubMedCrossRef

20.

Chaturvedi N, Sjolie A-K, Porta M et al (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284–289PubMedCrossRef

21.

Pambianco G, Costacou T, Orchard TJ (2007) The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30:1248–1254PubMedCrossRef

22.

Thorn LM, Forsblom C, Waden J, Finnish Diabetic Nephropathy (FinnDiane) Study Group et al (2009) Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 32:950–952PubMedCrossRef

23.

Sattar N, McConnachie A, Shaper AG et al (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371:1927–1935PubMedCrossRef

24.

Nathan DM, Cleary PA, Backlund JY, The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMedCrossRef

25.

The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef

26.

Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD (1998) Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 280:140–146PubMedCrossRef

27.

Purnell JQ, Dev RK, Steffes MW et al (2003) Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 52:2623–2629PubMedCrossRef

28.

Conway B, Miller RG, Costacou T et al (2009) Adiposity and mortality in type 1 diabetes. Int J Obes 33:796–805CrossRef

29.

Ferriss JB, Webb D, Chaturvedi N, Fuller JH, Idzior-Walus B, EURODIAB Prospective Complications Group (2006) Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure in type 1 diabetes. Diabet Med 23:557–564PubMedCrossRef

30.

Taylor AM, Dunger DB, Grant DB, Preece MA (1988) Somatomedin-C/IGF-1 measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls. Diabetes Res 9:177–181PubMed

31.

Edge JA, Dunger DB, Matthews DR, Gilbert JP, Smith CP (1990) Increased overnight growth hormone concentrations in diabetic compared with normal adolescents. J Clin Endocrinol Metab 71:1356–1362PubMedCrossRef

32.

Norbert S, Konstantinos K, Hans-Ulrich H (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939–960CrossRef

33.

Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749PubMedCrossRef

34.

Savage DB, Semple RK (2010) Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 21:329–336PubMedCrossRef

35.

Hodson L, Frayn KN (2011) Hepatic fatty acid partitioning. Curr Opin Lipidol 22:216–224PubMedCrossRef

36.

Christ ER, Carroll PV, Albany E et al (2001) Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. Clin Endocrinol 55:777–787CrossRef

37.

Vethakkan SR, Walters JM, Gooley JL et al (2012) Normalized NEFA dynamics during an OGTT after islet transplantation. Transplantation 94:e49–e51PubMedCrossRef

38.

Sinha R, Dufour S, Petersen KF et al (2002) Assessment of skeletal muscle triglyceride content by ¹H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 51:1022–1027PubMedCrossRef

39.

Yazici D, Ozben B, Yavuz D et al (2011) Epicardial adipose thickness in type 1 diabetic patients. Endocrine 40:250–255PubMedCrossRef

40.

Nikkila EA, Hormila P (1978) Serum lipids and lipoproteins in insulin-treated diabetes: demonstration of increased high density lipoprotein concentrations. Diabetes 27:1078–1086PubMed

41.

Taskinen MR (1992) Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 41:12–17PubMedCrossRef

42.

Colhoun HM, Taskinen MR, Otvos JD, Van Den Berg P, O’Connor J, Van Tol A (2002) Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 51:3300–3305PubMedCrossRef

43.

Guy J, Ogden L, Wadwa RP et al (2009) Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case–control study. Diabetes Care 32:416–420PubMedCrossRef

44.

Bain SC, Gill GV, Dyer PH et al (2003) Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabet Med 20:808–811PubMedCrossRef

45.

Prince CT, Becker DJ, Costacou T, Miller RG, Orchard TJ (2007) Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 50:2280–2288PubMedCrossRef

46.

Taskinen MR (1987) Lipoprotein lipase in diabetes. Diabetes Metabol Rev 3:551–570CrossRef

47.

James RW, Pometta D (1990) Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes 39:1158–1164PubMedCrossRef

48.

Caixas A, Perez A, Payes A et al (1998) Effects of short-acting insulin analog (Insulin Lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus. Metabolism 47:371–376PubMedCrossRef

49.

Sibley SD, Palmer JP, Hirsch IB, Brunzell J (2003) Visceral obesity, hepatic lipase activity, and dyslipidaemia in type 1 diabetes. J Clin Endocrinol Metab 88:3379–3384PubMedCrossRef

50.

Ruotolo G, Parlavecchia M, Taskinen MR et al (1994) Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity. Diabetes Care 17:6–12PubMedCrossRef

51.

Petruzzo P, Badet L, Lefrancois N et al (2006) Metabolic consequences of pancreatic systemic or portal venous drainage in simultaneous pancreas-kidney transplant recipients. Diabet Med 23:654–659PubMedCrossRef

52.

Frystyk J, Ritzel RA, Maubach J et al (2008) Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact of glucose regulatory hormones and the growth hormone/insulin-like growth factor axis. J Clin Endocrinol Metab 93:1758–1766PubMedCrossRef

53.

Nevalainen P, Lahtela JT, Mustonen J, Pasternack A (1997) The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients. Nephrol Dial Transplant 12:145–150PubMedCrossRef

54.

Selam J-L, Kashyap M, Alberti KGMM et al (1989) Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type 1 diabetes mellitus. Metabolism 38:908–912PubMedCrossRef

55.

Lahtela JT, Mustonen J, Pasternack A (1995) Comparison of intraperitoneal and subcutaneous insulin administration on insulin sensitivity and serum lipids in type 1 diabetic patients on continuous ambulatory peritoneal dialysis. Clin Sci 88:427–432PubMed

56.

Voight BF, Peloso GM, Orho-Melander M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:572–580PubMedCrossRef

57.

Livingstone SJ, Looker HC, Hothersall EJ et al (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 9:e1001321PubMedCrossRef

58.

Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR (2010) The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 53:809–820PubMedCrossRef

59.

REMOVAL: http://clinicaltrials.gov/ct2/show/NCT01483560?term=REMOVAL&rank=1

Title: Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?
Authors: S. J. Cleland
B. M. Fisher
H. M. Colhoun
N. Sattar
J. R. Petrie
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 7/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-013-2904-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2013

Heterogeneous nuclear ribonucleoproteins F and K mediate insulin inhibition of renal angiotensinogen gene expression and prevention of hypertension and kidney injury in diabetic mice

Oscillations of sub-membrane ATP in glucose-stimulated beta cells depend on negative feedback from Ca2+

Effects of immunosuppression on alpha and beta cell renewal in transplanted mouse islets

Consumption of sweet beverages and type 2 diabetes incidence in European adults: results from EPIC-InterAct

Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis

Functional differences between aggregated and dispersed insulin-producing cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page